Conformis Reports New Clinical Study Finds Bilateral Knee Conformis Reports Patients Prefer Conformis’ Fully Personalized Solution Over Competitive Off-the-Shelf Implants by a Factor of Over 10 to 1

Conformis, Inc. (NASDAQ:CFMS), the pioneer and leader of fully personalized orthopedic medical devices, today announced results of a published retrospective study of patients showing the superiority of Conformis’ implants in several key measures of clinical success and patient satisfaction.

According to the study published in The Journal of Bone & Joint Surgery Reviews (JBJS Reviews)1, patients who had undergone bilateral total knee arthroplasty (TKA) preferred their Conformis fully personalized knee compared to their bilateral off-the-shelf knee at a rate of more than 10 to 1.

The study surveyed 47 TKA patients who had a fully personalized Conformis implant in one knee after previously receiving a competitive off-the-shelf implant in their other knee. The study found that 72.3 percent of the patients studied preferred their fully personalized Conformis knee replacement, compared to 6.4 percent of patients who preferred their traditional off-the-shelf (OTS) implant. The remaining 21.3 percent reported no perceived difference between the two knee implants.

Conformis notes the study, believed to be the first ever to directly examine patient-reported outcomes comparing fully personalized and traditional off-the-shelf implants in the same patient as a control, underscores the higher levels of satisfaction and lower levels of pain and joint awareness associated with fully personalized implants. The patients reported less pain, better perceived mobility and a more “normal” feeling in the fully personalized Conformis implant.

“This study confirms what the surgeons and engineers working at Conformis have known from the beginning: a fully personalized knee replacement that is designed specifically for each patient’s unique anatomy and original motion clearly contributes to better clinical outcomes and happier patients,” said Mark Augusti, Chief Executive Officer and President of Conformis.

He added, “Our fully personalized knee system has demonstrated its clinical benefits in dozens of peer-reviewed studies over the years, and this patient self-controlled research further validates that the patients who are living with two different knee implants can feel the difference. Simply put, our fully personalized implants fit better and feel more natural.”

The patients in the study were evaluated using the well-established Knee Injury and Osteoarthritis Outcome Score, Joint Replacement (KOOS, JR), the Forgotten Joint Score (FJS) and preference questionnaire methodologies. “New technological advances in the past decades have fueled the race for the ‘happiest patient’ following total knee arthroplasty,” wrote the authors. “Patients in this study with bilateral knee joint replacement showed an overall preference for customized total knee arthroplasty.”

“Participants in the present study overall favored the custom total knee arthroplasty (C-TKA) over the standard prostheses in all surveyed categories: pain, motion, stability, ‘normal’ feel, and overall preference,” noted the authors. “On the basis of these findings, the combination of more precise implant fit and component rotation of C-TKA compared with OTS TKA may have been a contributing factor for lower pain levels and functional superiority, thus contributing to patients’ preference for customized over OTS TKA.”

Conformis has been a leader in patient specific technology since its founding in 2004. The company continues to innovate. Most recently, Conformis launched the Image-to-Implant® Platinum Services℠Program (PSP), the first deluxe personalization upgrade services program in the orthopedic market.


References

1. Schroeder, Lennart MD1,a; Dunaway, Andrew DO2; Dunaway, Daniel MD3 A Comparison of Clinical Outcomes and Implant Preference of Patients with Bilateral TKA, JBJS Reviews: February 2022 – Volume 10 – Issue 2 – e20.00182 doi: 10.2106/JBJS.RVW.20.00182

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version